Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2008-02-04 Regulatory Filings
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is titled "Pressmeddelande" (Press Release) and announces a research and development collaboration between Karo Bio and Zydus Cadila regarding new anti-inflammatory drugs. It details the nature of the agreement, the scientific rationale, and includes contact information and boilerplate descriptions of both companies. This type of announcement, detailing a strategic business event (a partnership/collaboration) rather than specific financial results (ER, IR), management changes (MANG), or regulatory filings (10-K, AR), fits best under a general announcement category. Since it is not a specific financial report, dividend notice, or insider trade, and it is a formal announcement, it is classified as a Regulatory Filing (RNS) as the most appropriate general category for non-standard corporate news releases, although it could also be considered a type of Capital/Financing Update (CAP) if the collaboration involved significant upfront payments or structuring, but RNS is safer for general partnership announcements not explicitly about financing or M&A.
2008-02-04 Swedish
Regulatory Filings 2008
Regulatory Filings Classification · 96% confidence The document announces a strategic research collaboration agreement between Karo Bio and Zydus Cadila for drug development targeting inflammatory diseases. This type of announcement, detailing a partnership, risk/reward sharing, and future development plans (pre-clinical studies, IND filing, clinical trials), is characteristic of corporate activity related to financing, strategic alliances, or M&A activity. Since it is not a formal regulatory filing (like 10-K or IR), nor a specific financial report (like ER or MRQ), nor a management change (MANG), it best fits the category for significant corporate transactions or strategic alliances. Given the options, 'M&A Activity' (TAR) is often used broadly for major strategic transactions, but 'Capital/Financing Update' (CAP) can sometimes cover strategic alliances that involve shared investment or future revenue streams. However, the core content is about a research collaboration agreement, which is a strategic business development event. Since there is no specific category for 'Strategic Alliance Announcement', and it is not a takeover bid (TAR), the most fitting general category for significant corporate news that isn't a standard financial report or management change is often captured under general regulatory announcements or sometimes related to financing/capital structure if future funding is implied. Given the nature of drug discovery partnerships, this is a significant business development event. If we must choose from the provided list, and it's not a formal M&A (TAR), it is a major corporate announcement. In many databases, such strategic deals fall under a general 'Corporate Action' or 'Regulatory Filing' (RNS) if no better fit exists. Since it details a major business agreement, and is not a standard financial report, I will classify it as a general Regulatory Filing (RNS) as it is a material announcement that doesn't fit the highly specific financial/governance codes, or potentially TAR if interpreted broadly as a 'transaction'. Given the context of drug development partnerships, RNS is the safest fallback for material, non-standard announcements. However, looking closely at the definitions, this is a material business development announcement. Since it is not a formal regulatory filing like a 10-K, and not a specific financial event, RNS (Regulatory Filings/Miscellaneous) is the appropriate fallback for significant corporate news that lacks a dedicated category.
2008-02-04 English
Legal Proceedings Report 2008
Legal Proceedings Report Classification · 99% confidence The document is titled "Pressmeddelande" (Press Release) and is dated January 17, 2008. It details progress on a drug candidate (Eprotirome/KB2115), including clinical trial recruitment status, publication of scientific data, and plans for future results presentation (Q3 2008). This content structure—announcing operational and scientific milestones via a press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it focuses on operational updates rather than just dividends (DIV) or management changes (MANG), it fits best as an Earnings Release (ER) which often includes key operational highlights alongside financial context, or RNS as a general announcement. Given the focus on clinical progress and upcoming results presentation, ER is a strong candidate, but since it lacks explicit quarterly financial figures (like revenue, EPS), RNS (Regulatory Filings - general announcement) is the safest classification for a non-standard operational update press release, especially since the document length is relatively short (3582 chars) and it functions as a general corporate update.
2008-01-17 Swedish
Earnings Release 2008
Earnings Release Classification · 95% confidence The document is explicitly titled 'Press release' and details clinical development progress, scientific publication updates (PNAS), enrollment status in a Phase IIb study, and expected timing for future data presentation (Q3 2008). This content structure—announcing key operational and scientific milestones via a press release format—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it focuses on operational updates and scientific progress rather than comprehensive financial statements (like 10-K or IR) or management compensation (DEF 14A), and it is a direct announcement rather than a link to a report (ruling 2), the most fitting category is Earnings Release (ER), as these often accompany or precede formal financial reporting periods with operational highlights. It is not a Call Transcript (CT) or a formal Audit Report (AR). Q3 2008
2008-01-17 English
Legal Proceedings Report 2007
Legal Proceedings Report Classification · 99% confidence The document is a press release dated December 4, 2007, announcing that Karo Bio has initiated Phase I clinical studies for its anti-diabetic substance KB3305. It details the purpose of the study (safety, tolerability, pharmacodynamics), the target patient population (healthy volunteers and Type 2 diabetes patients), and includes quotes from the CEO regarding progress. This type of announcement, detailing the start of a specific phase of drug development, is a standard corporate update. It is not a full Annual Report (10-K), an Earnings Release (ER) focusing on financial results, or a formal Audit Report (AR). Since it is a specific corporate announcement about a development milestone, it fits best under the general category of Regulatory Filings (RNS) as a press release, or potentially a general corporate update, but RNS serves as the best fit for non-standardized, time-sensitive corporate news releases that aren't explicitly covered by other codes like DIV or CAP. Given the options, RNS is the most appropriate catch-all for this type of operational/development news release.
2007-12-04 Swedish
Regulatory Filings 2007
Regulatory Filings Classification · 90% confidence The document is a press release announcing that Karo Bio has initiated Phase I clinical trials for its compound KB3305. It details the study design (safety, tolerability, pharmacodynamics) and provides background on the drug's mechanism and the company's focus. This type of announcement, detailing progress in drug development and clinical milestones, is typically classified as a general corporate update or regulatory filing, but it does not fit the specific definitions for Earnings Release (ER), Interim Report (IR), or Capital Update (CAP). Since it is a specific announcement about a corporate event (clinical trial initiation) that doesn't map cleanly to the other specialized categories (like M&A, Dividend, Board Change), it falls best under the general Regulatory Filings category (RNS) or potentially an Investor Presentation (IP) if it were a slide deck, but given the format, RNS is the most appropriate fallback for a significant, non-financial operational update.
2007-12-04 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.